MindRank

MindRank is an AI-powered drug discovery company that uses machine learning to accelerate small molecule drug development, with a focus on hard-to-drug molecular targets. The company's proprietary AI platform, Molecule Pro, leverages innovations in machine learning, biology, and chemistry to significantly accelerate the drug discovery process and deliver small molecule drugs with superior potency, druggability, and novelty. MindRank's lead proprietary drug MDR-001, an oral small-molecule GLP-1 receptor agonist for the treatment of obesity and type 2 diabetes mellitus, obtained US IND approval in just 19 months from program initiation and has entered Phase III clinical trials. The company has also successfully delivered an allosteric inhibitor preclinical candidate with best-in-class potential to a publicly traded biotech company. MindRank's team of over 40 scientists includes top biopharma experts and global AI competition winners, with innovations published in prestigious scientific journals including Nature Biomedical Engineering, Patterns (Cell Press), and Advanced Science, and conferences such as ICML, IJCAI, and KDD. The company was recognized as one of Forbes Asia's '100 to Watch' in 2023 and received funding from the Dynamic Resilience program launched by Wellcome Leap and Temasek Trust. Founded in 2019 and headquartered in Shanghai, China, with offices in London and Hangzhou, MindRank has raised $82.0M in Series B funding from investors including Huagai Capital, Green Pine Capital Partners, Sherpa Healthcare Partners, and Cher Ami.